ARTICLE | Company News
Crescendo, Takeda in deal for Humabodies
October 10, 2016 7:00 AM UTC
Crescendo Biologics Ltd. (Cambridge, U.K.) will use its transgenic mouse platform to discover and optimize Humabodies against undisclosed targets selected by Takeda Pharmaceutical Co. Ltd. (Tokyo:4502).
Humabodies are based on human variable antibody fragments. The companies said the deal is focused on generating tumor-targeting drug conjugates and immuno-oncology therapeutics. Takeda will be responsible for developing and commercializing Humabody-based therapeutics resulting from the collaboration. ...